Gastric Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Gastric clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 567 trials

Recruiting
Phase 1

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled36 locationsNCT06995898
Recruiting
Phase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines140 enrolled19 locationsNCT06427941
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Esophageal CancerGastric CancerGastroesophageal-junction Cancer+2 more
Washington University School of Medicine42 enrolled1 locationNCT05187182
Recruiting
Phase 2

Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma

Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University48 enrolled1 locationNCT07277439
Recruiting
Phase 1

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Gastric AdenocarcinomaGEJ AdenocarcinomaPDAC - Pancreatic Ductal Adenocarcinoma+4 more
Avacta Life Sciences Ltd144 enrolled2 locationsNCT07454642
Recruiting

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria

Gastric CancerGastric (Stomach) CancerGastric Cancer (Diagnosis)
Société Algérienne de Formation et Recherche en Oncologie1,000 enrolled2 locationsNCT07481110
Recruiting
Phase 2

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer
AstraZeneca163 enrolled44 locationsNCT05702229
Recruiting
Phase 1

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

Colorectal CarcinomaGastric CarcinomaPancreatic Ductal Adenocarcinoma
Boehringer Ingelheim135 enrolled3 locationsNCT06882746
Recruiting
Not Applicable

Resilience and Equity in Aging, Cancer, and Health (REACH)

Esophageal CancerPancreatic CancerGastric Cancer+3 more
Dana-Farber Cancer Institute257 enrolled1 locationNCT04674267
Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled17 locationsNCT06921928
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1Phase 2

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Triple-Negative Breast CancerMelanomaNon-small Cell Lung Cancer+6 more
AstraZeneca60 enrolled11 locationsNCT07115043
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled369 locationsNCT06203600
Recruiting
Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

Esophageal CancerGastric Cancer (GC)Gastroesophageal Junction
SOFIE200 enrolled10 locationsNCT07217704
Recruiting
Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Phase 3

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478